TrialInternational journal of clinical oncology2019

The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.

Aristotelis Bamias et al.PubMed ↗Publisher ↗

No numbers read from the abstract.